Eli Lilly and Company (NYSE:LLY) Shares Sold by United Community Bank

United Community Bank trimmed its stake in shares of Eli Lilly and Company (NYSE:LLY) by 21.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,602 shares of the company’s stock after selling 448 shares during the quarter. United Community Bank’s holdings in Eli Lilly and Company were worth $1,246,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Simon Quick Advisors LLC raised its stake in shares of Eli Lilly and Company by 10.5% during the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock worth $1,706,000 after buying an additional 278 shares in the last quarter. Independent Advisor Alliance raised its stake in shares of Eli Lilly and Company by 1.7% during the 4th quarter. Independent Advisor Alliance now owns 32,269 shares of the company’s stock worth $18,810,000 after buying an additional 544 shares in the last quarter. Apexium Financial LP increased its stake in Eli Lilly and Company by 1,819.1% in the 4th quarter. Apexium Financial LP now owns 11,438 shares of the company’s stock valued at $6,667,000 after purchasing an additional 10,842 shares in the last quarter. Clear Harbor Asset Management LLC purchased a new position in Eli Lilly and Company in the 4th quarter valued at approximately $363,000. Finally, Terril Brothers Inc. increased its stake in Eli Lilly and Company by 113.2% in the 4th quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock valued at $471,000 after purchasing an additional 429 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 0.6 %

Eli Lilly and Company stock traded up $5.95 during midday trading on Wednesday, hitting $938.45. The stock had a trading volume of 641,582 shares, compared to its average volume of 2,921,544. The stock has a market cap of $891.91 billion, a P/E ratio of 138.21, a P/E/G ratio of 2.00 and a beta of 0.41. The business has a fifty day moving average price of $838.34 and a 200 day moving average price of $757.52. Eli Lilly and Company has a 12 month low of $434.34 and a 12 month high of $939.98. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business’s revenue was up 26.0% compared to the same quarter last year. During the same period in the prior year, the company earned $1.62 earnings per share. Research analysts predict that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.55%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 93,593 shares of the company’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $918.64, for a total transaction of $85,978,273.52. Following the completion of the transaction, the insider now directly owns 97,153,810 shares of the company’s stock, valued at $89,249,376,018.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, major shareholder Lilly Endowment Inc sold 93,593 shares of the business’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $918.64, for a total transaction of $85,978,273.52. Following the completion of the transaction, the insider now directly owns 97,153,810 shares in the company, valued at $89,249,376,018.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the transaction, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,004,704 shares of company stock valued at $869,479,116. 0.13% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have weighed in on LLY. Citigroup raised their price target on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. The Goldman Sachs Group lifted their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. BMO Capital Markets reiterated an “outperform” rating and issued a $1,001.00 target price on shares of Eli Lilly and Company in a report on Wednesday, July 3rd. Truist Financial restated a “buy” rating and set a $1,000.00 price objective (up previously from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a research note on Monday, July 1st. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $816.78.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.